《新股消息》微創機器人-B(02252.HK)暗盤收40.15元 低上市價7.1%
微創醫療(00853.HK)分拆的微創機器人-B(02252.HK)將於明日(2日)在主板掛牌,根據輝立交易場顯示,微創機器人暗盤開報44元,較每股定價43.2元高出1.85%,但隨後掉頭低見38.5元,收報40.15元,較上市價低7.1%或3.05元,成交118萬股,涉資4,750萬元。不計手續費,每手500股,賬面蝕1,525元。
微創機器人香港公開發售錄得超額認購約162.83倍,以招股範圍(介乎36元至43.2元)上限定價,認購一手中籤率3.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.